Skip to main navigation
Intercept Pharmaceuticals homepage
  • News
  • Contact Us
Intercept Pharmaceuticals Logo
Menu
Close✕
  • Our Focus
    • Rare and Serious Liver Diseases
      • Meet Ally
      • Racial Disparities in PBC
    • Patient Resources
  • Our Research
    • FXR
    • Pipeline
      • Expanded Access
    • Clinical Trials
    • Medical Information Request Form
  • Our Medicine
  • About Us
    • Leadership
    • News
    • Company Statements
  • Careers
    • Job Postings
    • Culture
    • US Benefits
  • Media
  • Contact Us
Home > Our Research > Clinical Trials

Ongoing
CLINICAL TRIALS

Nishele, Living with PBC
  • Our Research
    • FXR
    • Pipeline
      • Expanded Access
    • Clinical Trials
    • Medical Information Request Form
    • Medical Information Request Form

Learn more about ongoing Intercept-sponsored clinical trials below.

 

Primary biliary cholangitis (PBC)

Intercept has two Phase 2 studies, 747-213 and 747-214, that are designed to explore a range of therapeutic doses for the combination of OCA and bezafibrate. Study 747-213 is for patients outside of the United States. Study 747-214 is for patients in the United States.

Learn more about Study 747-213Learn more about Study 747-214

 

Severe alcohol-associated hepatitis (sAH)

The Phase 2a FRESH (FXR Effect on Severe Alcohol-Associated Hepatitis) study is a randomized, double-blind, dose-escalation study that is expected to enroll approximately 50 patients with saH across multiple clinical sites in the U.S., UK and France. The study aims to demonstrate and provide rationale for the selection of optimal dose(s) of INT-787 in the target patient population.

Learn more

 

Investigational uses and have not been approved by the FDA or any other worldwide regulatory agency. Safety and efficacy have not been established.

  • Our Focus
    • Rare and Serious Liver Diseases
      • Meet Ally
      • Racial Disparities in PBC
    • Patient Resources
  • Our Research
    • FXR
    • Pipeline
      • Expanded Access
    • Clinical Trials
    • Medical Information Request Form
  • Our Medicine
  • About Us
    • Leadership >
    • News >
  • Careers
    • Job Postings
    • Culture
    • US Benefits
Intercept Pharmaceuticals Logo
  • Website Privacy Policy
  • Consumer Health Data Privacy Policy
  • EU-US Data Privacy Framework (DPF) Policy
  • Corporate Compliance
  • Terms of Use
  • Contact Us
  • Cookie Preferences
  • Transparency Disclosures
305 Madison Avenue |Morristown, NJ 07960|T: (844) 782–4278
© 2024 Intercept Pharmaceuticals, Inc.
US-NP-PB-1859
US-NP-PB-1859

YOU ARE NOW leaving interceptpharma.com


You are now leaving Intercept Pharmaceuticals’ corporate website and entering a site intended for U.S. audiences only.

Continue

YOU ARE NOW leaving interceptpharma.com


You are now leaving Intercept Pharmaceuticals’ corporate website. Intercept does not control or endorse the content of this external site.

Continue

YOU ARE NOW leaving interceptpharma.com


The link you have selected will take you outside of Intercept Pharmaceuticals’ corporate website.
The site you will be entering is intended for U.S. audiences only.

Continue


If you are a healthcare provider looking for product information, visit ocalivahcp.com.

YOU ARE NOW leaving interceptpharma.com


You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents. Intercept provides this link as a service to its website visitors. Intercept is not responsible for the content or the privacy policy of any third party websites.

Close this window to return to Intercept Pharmaceuticals’ site or click ‘Continue’ to proceed.

Continue

United States (US)
European Union (EU)
Canada
Israel
Switzerland
Australia
Liechtenstein
United Arab Emirates (UAE)

Close

Exploring Racial Differences and Disparities in PBC Care